TCGA-E2-A15T-01A-11R-A115-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 52
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.390
- PROTEIN_SECRETION+0.380
- E2F_TARGETS+0.360
- G2M_CHECKPOINT+0.340
- ESTROGEN_RESPONSE_EARLY+0.260
- MYC_TARGETS_V1+0.230
- TGF_BETA_SIGNALING+0.190
- DNA_REPAIR+0.170
- UNFOLDED_PROTEIN_RESPONSE+0.170
- SPERMATOGENESIS+0.160
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.590
- ALLOGRAFT_REJECTION-0.580
- INTERFERON_GAMMA_RESPONSE-0.530
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.520
- IL6_JAK_STAT3_SIGNALING-0.510
- INFLAMMATORY_RESPONSE-0.480
- COAGULATION-0.360
- KRAS_SIGNALING_UP-0.340
- TNFA_SIGNALING_VIA_NFKB-0.340
- ANGIOGENESIS-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A155-01A-11R-A12D-07 | — | B | 0.911 |
| 2 | TCGA-A8-A0AB-01A-11R-A034-07 | — | B | 0.908 |
| 3 | TCGA-A2-A1G4-01A-11R-A13Q-07 | — | B | 0.901 |
| 4 | MDT-AP-3307 | Med | Medulloblastoma | 0.898 |
| 5 | TCGA-E9-A1R7-01A-11R-A14M-07 | — | B | 0.885 |
| 6 | TCGA-E9-A1RC-01A-11R-A157-07 | — | B | 0.883 |
| 7 | MDT-AP-3021 | Med | Medulloblastoma | 0.882 |
| 8 | TCGA-E2-A1IE-01A-11R-A13Q-07 | — | B | 0.880 |
| 9 | MDT-AP-3402 | Med | Medulloblastoma | 0.879 |
| 10 | TCGA-GC-A4ZW-01A-11R-A26T-07 | — | — | 0.878 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.390 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.190 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.170 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.130 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.120 | Inavolisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.090 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.080 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.070 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.060 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.060 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.050 | Inavolisib | — uncovered |